GH vs GRAL
GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum. GRAL: GRAIL is a pioneer in multi-cancer early detection, developing blood-based tests designed to identify multiple types of cancer at earlier, more treatable stages.
Side-by-side fundamentals
| Metric | GH | GRAL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $165.56 | $132.61 | |
| Market cap | $22.2B | $5.9B | |
| Net margin FY2025, SEC XBRL | -42.4% | -277.5% | GH higher |
| Operating margin FY2025, SEC XBRL | -44.5% | -382.0% | GH higher |
| ROE FY2025, SEC XBRL | n/a | -15.8% | |
| ROA FY2025, SEC XBRL | -20.7% | -14.0% | GRAL higher |
| Debt / equity as of 2026-09-03 | 16.78 | 0.00 | GRAL lower |
| Revenue growth (YoY) as of 2026-09-03 | +42.7% | +23.1% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | +25.7% | GH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.23 | 2.57 | |
| 1-year return as of 2026-10-08 close | +153.5% | +82.2% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.